Bayer, Johnson and Johnson Win Third U.S. Trial Over Xarelto Bleeding Risk Bayer, Johnson and Johnson Win Third U.S. Trial Over Xarelto Bleeding Risk

A federal jury has cleared Bayer AG and Johnson and Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers ' blood thinner Xarelto (rivaroxaban) led to severe internal bleeding.Reuters Health Information
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news